Alteogen will handle the regulatory development and commercial supply of its hyaluronidase to Sandoz. Credit: National Cancer Institute / Unsplash.

South Korean biotechnology company Alteogen has signed an exclusive licence agreement with Swiss company Sandoz to develop and market biosimilar products enabled by the former’s Hybrozyme technology.

Under the agreement, Sandoz will have the global rights to use Alteogen’s novel hyaluronidase, ALT-B4, for the development and commercialisation of a subcutaneous version of a biosimilar product.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Additionally, the company will have the option to license Alteogen’s Hybrozyme technology for two more products.

Alteogen will handle the regulatory development and commercial supply of its hyaluronidase to the Swiss company.

Developed using the Hybrozyme technology, ALT-B4 is Alteogen’s proprietary human recombinant human hyaluronidase enzyme.

According to the agreement, Alteogen will receive an upfront payment along with payments after Sandoz achieves milestones on specified development, regulatory and sales aspects.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The South Korean company will also be eligible to receive tiered royalties based on the sales of the commercialised product.

Alteogen CEO Dr Soon Jae Park said: “We are pleased to enter into this agreement with a pioneering company like Sandoz, which has a global presence and an unparalleled track record of bringing high-quality biosimilars to market.

“We look forward to a productive and constructive collaboration bringing multiple products to the market for the benefit of patients.

“Both companies share a belief in the necessity of increasing patient access to high-quality biosimilars.”

Regarding the two option products covered in this deal, Alteogen and Sandoz will negotiate different agreements during exercising each option.

The deal enables the two companies to work together on developing and commercialising additional products that Sandoz may choose to develop.